Company intelligence / Profile preview

Nanox

Petah Tikva, Central District, Israelinvestors.nanox.vision ↗

Ownership: Public · NNOX
Employees: ~250
Development stage: Commercial

Overview

Nanox has received FDA 510(k) clearance for its multi-source digital tomosynthesis system (Nanox.ARC), which enables advanced 3D body visualization at lower cost and radiation dose compared to traditional systems. Its AI solutions have demonstrated improved early detection of chronic diseases such as osteoporosis and coronary artery disease in real-world studies with partners like Corewell Health and the UK NHS. Over 60 units are in various stages of implementation globally as of Q1 2025.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularRheumatologyEndocrinology
Modalities: DeviceArtificial intelligence software
Industry: Medical Imaging

Partnerships

Corewell HealthAtlantic Health SystemBeilinson Hospital/NHS sites for clinical studies and deployments

Financials

Market cap: $64.7M
Total revenue: $4.3M
Enterprise value: $28.5M

Beyond the preview

Go deeper on Nanox.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanox.

Explore the full profile